Table 1 Baseline characteristics and summary of included studies
study | Type study | Sample size | Age (years), Mean (SD) | Sex (male/female) | Weight (kg), Mean (SD) | Height (cm), Mean (SD) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Se | placebo | Se | placebo | Se | placebo | Se | placebo | Se | placebo | ||
Shahram Amini 2018 [2] | RCT | 66 | 71 | 58.21(10.54) | 58.72(8.57) | NA | NA | 74.93(14.01) | 72.56(12.48) | 166.77(9.03) | 165.4(10.12) |
Mette M Berger 2008 [9] | RCT | 57 | 56 | 69( 8) | 71(11) | 70/43 | 70/43 | 75(16) | 74( 17) | NA | NA |
Tanja Schmidt 2018 [10] | RCT | 206 | 205 | 66 (11) | 68 (10) | 150/56 | 152/53 | 81 (18) | 80 (16) | 170 (13) | 170 (11) |
Christian Stoppe 2023 [3] | RCT | 697 | 697 | 68.0 (10.0) | 68.5 (10.8) | 513/184 | 530/167 | NA | NA | NA | NA |
Abbas Sedighinejad2016 [4] | RCT | 41 | 40 | 54.65 (8.46) | 58.2 ( 8.29) | 20/21 | 21/19 | NA | NA | NA | NA |
Abbas Ali Zeraati 2021 [1] | RCT | 60 | 60 | 51.1(15.2) | 54.1(17.4) | NA | NA | NA | NA | NA | NA |
Laaf 2022 [11] | RCT | 10 | 10 | 63.8 (10.9) | 61.5 (8.1) | 10\0 | 9\1 | NA | NA | NA | NA |
study | Body mass index, Mean (SD) | Coronary artery disease (N) | Diabetes (N) | Ejection fraction, Mean (SD) | Doses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Se | placebo | Se | placebo | Se | placebo | Se | placebo | before | after | total | |
Shahram Amini 2018 [2] | 26.92(4.62) | 26.54(4.31) | 6 | 3 | 26 | 20 | 53.17(7.06) | 50.58(6.42) | 0. 5 mg | 0.5mg | 1.0mg |
Mette M Berger 2008 [9] | 26.7 (5.3) | 26.2 (4.7) | NA | NA | NA | NA | NA | NA | NA | 540.4μg,and 270.2μg | 1991.4 μg |
Tanja Schmidt 2018 [10] | 27 (5) | 28 (4) | 115 | 122 | 42 | 46 | 55 (17) | 54 (18) | NA | 4000μg | 5000μg |
Christian Stoppe 2023 [3] | 28.9 (5.3) | 28.2 (5.2) | 124 | 108 | 171 | 173 | 55 (7.42) | 55 (7.42) | 2000 μg/L | 2000 μg/L then 1000 μg/L | 21,000 μg in 8 days |
Abbas Sedighinejad 2016 [4] | 27.16 ( 3.03) | 27.32 ( 2.37) | NA | NA | NA | NA | 47.31( 7.42) | 47.87 ( 3.9) | 600 μg | NA | NA |
Abbas Ali Zeraati 2021 [1] | 23.5(4.3) | 25.3(3.8) | 2.16 | 4.26 | 10.74 | 21.4 | NA | NA | 500 μg | 500 μg | 3000 μg |
Laaf 2022 [11] | 30.0 (3.9) | 29.8 (6.9) | 3 | 4 | NA | NA | 18 (5.2) | 21 (6.5) | 300mcg | 3000mcg then 1000mcg | 18000mcg |